Warfarin Accelerates Medial Arterial Calcification in Humans.

Autor:	Alappan HR; From the Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA., Kaur G; From the Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA., Manzoor S; From the Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA., Navarrete J; From the Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA., O'Neill WC; From the Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Jazyk:	angličtina
Zdroj:	Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2020 May; Vol. 40 (5), pp. 1413-1419. Date of Electronic Publication: 2020 Feb 13.
DOI:	10.1161/ATVBAHA.119.313879
Abstrakt:	Objective: Warfarin is associated with medial arterial calcification in humans, but the magnitude and specificity of this effect and the role of other risk factors are unknown. Using serial mammograms, progression of arterial calcification was compared in women receiving no anticoagulants, warfarin, or other anticoagulants, and before, during, and after warfarin use. Approach and Results: Warfarin users with mammograms were identified by computerized searches of medical records that included renal function and diabetes mellitus. Lengths of calcified arterial segments were measured, with progression expressed as millimeters per breast per year and presented as medians and interquartile range (IQR). In women with normal renal function (estimated glomerular filtration rate >60 mL/minute per 1.73 m 2 ), progression was 3.9-fold greater in warfarin users: 9.9 (3.8-16) versus 2.5 (0.7-6.7) in controls, P =0.0003, but not increased in users of other anticoagulants. In longitudinal analyses, progression increased from 2.1 (IQR, 0.3-3.9) to 13.8 (IQR, 7.8-38.7; P =0.011) after starting warfarin (n=11) and decreased from 8.8 (IQR, 1.1-10) to 1.9 (IQR, -10 to 6.7; P =0.024) after discontinuation of warfarin (n=13). Progression of calcification was similar in warfarin users with chronic kidney disease (7.3 [IQR, 3.6-17], n=29) but markedly accelerated in warfarin users with end-stage renal disease (47 [IQR, 31-183], n=11; P =0.0002). Progression was similar in diabetic and nondiabetic warfarin users (10.1 [IQR, 3.8-24] versus 7.8 [IQR, 3.6-15]) and did not correlate with age ( r =0.09) or duration of warfarin therapy ( r =0.12). Conclusions: Warfarin significantly accelerates medial arterial calcification in humans. This effect is markedly augmented in end-stage renal disease.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu